Chester thanks for the heads up - good news !
Mia wow - "trailblazing potential for the ImmunoBody® platform in further improving the survival rates in patients with unresectable melanoma".
I LIKE it ! Still to come - iSCIB1+ . . . . in respect of which we already have a confident prediction that we'll LOVE it !
Trailblazing indeed !
Dracula - "SHs and Sclp need something to stop the SP decline. Sclp seem to have the goods. What happens If the SP keeps falling... a cheap buyout?." It was you I was thinking of when I posted "Other Posters seem to quietly lay the ground . . . " and TBH you seem to be a quiet 'disrupter', carefully disguising with a sometimes positive comment in posts as in your last.
As for your mischievous "a cheap buyout?" - not a chance in hell old Chap.
Violin - "effectively block a cheap takeover . . . ride out the SP decline for the anticipated promised reward ... I guess all is well." I don't think there is any 'promised reward' BUT IMO there is no way this genius Scancell team will fall for anything like that.
Violin - your 'jolly day' will IMHO arrive. ATB
Nice typo WTP - changing Burble to Buble (Michael?) and I'm not sure why you apologised.
Burble is on track as usual and WTP you commented - "they do seem to be hitting the conference circuit harder than normal?"
I think you are right! Since AACR in April it's been ICIC Sep 20-23, WVC(E) Oct 19, WVC Oct 19, SITC Nov 1-5 and now PEGS Nov14th. For me that's a veritable stream of promising activity . . . .
I'll resist the temptation to conclude there are hopeful 'discussions' underway, (if discussions are needed they can be held anytime), but it's my impression that a LOT more disseminating of data and networking IS going on. So well done to Scancell.
And well done to Prof. Lindy who is doing well as CEO IMO. So PEGS is coming up with our 'Principal Scientist' in action AND we have our new BDO to bang the Scancell drums. GLA
Violin I profoundly disagree with - "Good posts this evening. It does look like it's another extended wait . . . . "
C11's earlier post 11.03 one of the few worth reading here today and Bojo 15.21 was spot on here - "What do you want? Blood!?!? . . . . Finally, I am sure that the pharma world understands exactly what Scancell are doing and when the time is right, more deals will get done."
Other Posters seem to quietly lay the ground for more polishing of every Scancell peanut with fevered impatience shining through. I'm afraid for me it's been a tiresome read atm but GLA.
Violin maybe after those delays, the Analysts/Investors meet has been dropped as the AGM is so close.
It's good we have a CBO in place now but any new avenues she generates will take some time to progress.
But you never know. We have the SITC Posters and the AGM to look forward to anyway and always the possibility something will come 'out of the blue'.
Keep smiling Violin - watching the kettle will tire you out. ATB
CW - re. SITC and the awaited Poster - 'Abstract number 1533 Session date and time Friday, Nov. 3, 2023, 9am - 7pm EDT" The footnote to the RNS as follows 'A copy of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications '
The poster is entitled 'A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE trial'
I had a look at the link above and I can't see that Poster yet.
Something to look forward to . . . . ! ATB
Hi Cleaner - the earlier data will be 'new' to some so for me the Jury is out on this one. I hope you are right though ! Data 'new' to us close followers please! ATB
Please Guys can we get back to Scancell tomorrow and never mention this stuff again on this serious BB for Investors. GN
Please Guys can we get back to Scancell tomorrow and never mention this stuff again on this serious BB for Investors. GN
Snippets from PoG :-
Inan 6784 - "composition of matter patent i suspect this is iscib1"
Inan 6785 - "so that could take Iscib1 to 2043 exclusivity"
Marcus 6786 - "What makes you think iScib Inan ?"
Inan 6787 - "because scancell have to file patent before its made public ie used in trial"
Marcus 6788 - "Could it be Moditope though?"
SCI102 6789 - "Could be anything including moditope, scib, iscib or anything else vaccine related."
Inan 6791 - "modi1 is a combination vaccine ... i do not know how this would apply ... its actually 3 vaccines .... each linked to the adjuvant"
Nigel 6792 - "I think Inanaco's assumption is likely to be the correct one".
Interesting - 2043 expiry sounds better. I'm 'loving' iSCIB1 already!
WF re. your 17.20 and 18.00 re. 'more' and the SITC Poster.
"Either that means sharing what we already know more" - yes even if the data is the same, maybe we have to put up the Poster as part of SITC procedures?
"Or sharing more data we don’t already know?" - in this happy event it would likely be price sensitive so we would get an RNS first thing?
An interesting teaser you have found and thanks - but doesn't the Poster have to be approved by SITC at an earlier time?
But an update RNS would be nice !
Hi CW. Yes Prof. Lindy will do some networking but a 'late speaking slot' - not sure if that happens. Anyway, it's all good . . . .
Yes EE and if I remember correctly, Inan copied a message he sent to CSO after that trial news was released, asking in words to the effect of, what's turning the T-cells off? The reply was cryptic . . . . (I don't have the stamina to look that one up!)
As you say, maybe they can make progress with that!
No RNS today so I just want to reiterate that if/when any deal arrives, deposits and payments received will extend this cash runway beyond some time in 2025 as certified by our Auditors.
It seems to me that the probability is high and after all, even another relatively 'paltry' £5 million is broadly 6 months operations. A single 'milestone payment' from Genmab, ($208 million), would of course be transformational!
I enjoyed this list that Ray P posted on 31/10 :-
"1 Scope trial continues to produce great results
2 Initial iSCIB1+ results exceed those of SCIB1
3 Initial Modi1 with CPI results are looking to probably far exceed current standard of care
4 Genmab first stage payment
5 2nd Glycans deal
6 CAR-T Glycans deal "
It looks a long list to me and of course, it's possible that something else might arise. Scancell really do seem to have some momentum now!
Thanks Bermuda - exciting news and thanks also to Konar and C11 for adding more thoughts. Scancell have some real momentum it seems, at last!
JB thanks for the thread but it's your choice of header that for me is 'strange' not the AGM being held at Cooleys - it's an excellent venue surely. However I wouldn't assume that there's any intrigue in that choice.
EE observes - "It seems to me that the advisers’ roster is now perfectly equipped for deals ahead…" Indeed so.
Doubts expressed earlier about combining the CEO/CSO roles were understandable but I think we can be reassured by now- IMO the CEO role is being carried out with some aplomb by Prof. Lindy and we now have excellence in all important in-house roles and are 'perfectly equipped' with Advisors.
So it's onwards and upwards for me and a well done to Prof. Lindy and the team. Plus good luck to CFO Sath and CBD Dr Mandeep in their new roles.
Johnny I always enjoy your posts. However, with the hectic nature of today's arrival of the admittedly long awaited report, maybe there hasn't been time to arrange the Inv/Ana Q & A as well. I'm sure we will hear soon when the CEO and CFO and the Venue is available.
It won't be very long before we know and also I think Scancell will be excited to do it - unless my Friend Violin intends to participate (wink).
I would love to be wrong but I doubt that the absence of this rearrangement right now, means there is a deal any time very soon. All good fun.
Thanks Ray and the point IMHO is that in looking forward to assure the 'financial integrity' of Scancell, the Auditors, who I am sure have done a thorough if belated job, can only include in their assumptions of viability, known or prudent stuff. Like what is assured.
(Sorry I have had 2 celebratory beers or I'd find the right terms).
IMHO any new deals involving further deposits or something more, are not likely to be included at all in this report and will be a whoohoo if/when such event happens.
Ciaskin good post. GNA
Paul I don't think you are correct there - it wouldn't be 'prudent' would it?
So if we get such 'revenue', that would be an extra. IMHO
Operating loss down to £11.9 from £13.3 million. CEO - "Revenue from the licencing deal with Genmab of £5.3 million reduced the operating loss significantly."
In the Chairman's words, "Remarkable initial data from 11 patients showed an 82% objective response rate (ORR) to treatment with no increase in toxicity, better than 70% ORR that the trial was configured to show. We are excited because, to our knowledge, no other combination has achieved this response rate with doublet checkpoint inhibitors in unresectable metastatic melanoma. Confirmation of this data in a larger cohort could make a significant impact on melanoma patient survival, especially as melanoma is now the most common cancer in young women and is increasing in incidence."
MMmmm REMARKABLE!
J-M C again, "We believe the impressive data from the SCOPE trial, combined with further near-term milestones and commercial opportunities will soon provide exciting inflection drivers." Inflection DRIVERS eh? More than one inflection point!
I couldn't see thanks being proffered to BDO for making the deadline in difficult circumstances LOL but at least the alarmed can take comfort from this, "The auditors issued an unqualified audit opinion which did not contain any statement under section 498(2) or 498(3) of the Companies Act 2006." As discussed, the 'delay' was never because of a problem within Scancell itself.
Perhaps we'll be told soon when the previously planned Q & A for Investors and Analysts will be taking place.
Back to normal then - just waiting for data and deals GLA